Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730326 | 0.83 | ENPP2 (0.45) | ENPP2PTGS2DAOAKR1C3 | |
| SCHEMBL8307666 | 0.81 | ENPP2 (0.43) | ENPP2PTGS2AKR1C3KCNJ1KCNH2 | |
| SCHEMBL23691719 | 0.80 | CA2 (0.33) | — | |
| SCHEMBL21277861 | 0.80 | PSIP1 (0.61) | — | |
| SCHEMBL28830799 | 0.79 | ENPP2 (0.47) | ENPP2PTGS2DAOAKR1C3EPHX2 | |
| SCHEMBL10453222 | 0.79 | ENPP2 (0.42) | ENPP2PTGS2DAOAKR1C3 | |
| SCHEMBL10453223 | 0.79 | ENPP2 (0.42) | ENPP2PTGS2DAOAKR1C3 | |
| SCHEMBL10453221 | 0.79 | ENPP2 (0.42) | ENPP2PTGS2DAOAKR1C3 | |
| SCHEMBL1750419 | 0.79 | ENPP2 (0.50) | ENPP2PTGS2DAOKCNJ1KCNH2 | |
| SCHEMBL13231429 | 0.78 | ENPP2 (0.54) | ENPP2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
| EP-1542972-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1527045-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011421-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-02-05 | — | — | WO | disclosed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1023277-A1 | NOVEL 3,4-DIARYLTHIAZOLIN-2-ONE OR -2-THIONE DERIVATIVES, PREPARATION METHODS AND USES IN THERAPY | LABORATOIRES UPSA (FR) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999018093-A1 | NOVEL 3,4-DIARYLTHIAZOLIN-2-ONE OR -2-THIONE DERIVATIVES, PREPARATION METHODS AND USES IN THERAPY | LABORATOIRES UPSA (FR) | 1999-04-15 | — | — | WO | disclosed |
| US-5859036-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | LABORATORIES UPSA (FR) | 1999-01-12 | — | — | US | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | ENPP2 702/4885PTGS2 4772/4885DAO 4306/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ENPP2 702/4885PTGS2 4772/4885DAO 4306/4885 |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ENPP2 702/4885PTGS2 4772/4885DAO 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.